<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is one of the most important <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000855'>Insulin-resistance</z:hpo> represents the common mechanism that leads to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> subjects </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> is an insulin-sensitizing agent available for treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Large clinical trials have demonstrated the effectiveness of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in achieving metabolic control and reducing <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality </plain></SENT>
<SENT sid="4" pm="."><plain>AIM: The purpose of this article is to review the effectiveness and tolerability of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in the prevention and management of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>EVIDENCE REVIEW: We reviewed the main monotherapy and comparative studies of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, and particularly the recent evidence in the field of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and cardiovascular prevention </plain></SENT>
<SENT sid="6" pm="."><plain>PLACE IN THERAPY: The current evidence shows that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> is an effective option in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>More studies are needed to establish a role for <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> prevention beyond glycemic control </plain></SENT>
</text></document>